Financial Analysis: Synaptogenix (TAOX) and The Competition

Synaptogenix (NASDAQ:TAOX) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Synaptogenix to similar businesses based on the strength of its valuation, profitability, institutional ownership, risk, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of current ratings for Synaptogenix and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Synaptogenix Competitors	7782	13876	25770	1035	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.24%. Given Synaptogenix’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Synaptogenix has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Synaptogenix has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Synaptogenix’s rivals have a beta of -3.66, suggesting that their average share price is 466% less volatile than the S&P 500.

Earnings & Valuation

This table compares Synaptogenix and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Synaptogenix	$772,499.00	-$28.74 million	-0.64
Synaptogenix Competitors	$5.42 billion	$3.22 billion	550.73

Synaptogenix’s rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Synaptogenix and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Synaptogenix Competitors	-2,381.29%	-218.58%	-15.77%

Summary

Synaptogenix rivals beat Synaptogenix on 10 of the 13 factors compared.

Synaptogenix Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.